Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide

Oncologist

Volumn 7, Issue SUPPL. 1, 2002, Pages 1-13

  Slack, James L ^a   Waxman, Samuel ^b   Tricot, Guido ^c   Tallman, Martin S ^d   Bloomfield, Clara D ^e  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Hematologic malignancy; Multiple myeloma

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; DEXAMETHASONE; IDARUBICIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BLOOD DYSCRASIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HISTORY OF MEDICINE; HODGKIN DISEASE; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SURVIVAL RATE;

EID: 0036214658     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_1-1     Document Type: Conference Paper

References (103)

1. Acute promyelocytic leukemia
2. Proposals for the classification of the acute leukaemia
3. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia
4. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid
5. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML
6. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus
7. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17
8. Structure, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins
9. Acute promyelocytic leukemia
10. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): Results of the European Working Party
11. Deconstructing a disease: RARα its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
12. Positive and negative regulation of granulopoiesis by endogenous RARα
13. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RARα or PML
14. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia
15. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells
16. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia
17. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements
18. Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells
19. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukaemia
20. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
21. PML, a growth suppressor disrupted in acute promyelocytic leukemia
22. The PML gene encodes a phosphoprotein associated with the nuclear matrix
23. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins
24. Management of acute promyelocytic leukemia relapse in the ATRA era
25. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia
26. Role of the histone deacetylase complex in acute promyelocytic leukaemia
27. Histone acetylation in chromatin structure and transcription
28. A positive role for histone acetylation in transcription factor access to nucleosomal nucteosomat DNA
29. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
30. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL
31. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
32. The unique aspects of acute promyelocytic leukemia
33. Prophylactic heparin therapy in acute promyelocytic leukemia
34. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia
35. Acute promyelocytic leukemia. Therapy results and prognostic factors
36. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital
37. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
38. Current issues in the management of acute promyelocytic leukemia
39. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
40. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results
41. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
42. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience
43. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study
44. All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases
45. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia
46. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
47. A randomized comparison of all-trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
48. All-transretinoic acid in acute promyelocytic leukemia
49. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
50. Ai-Lin I treated 32 cases of acute promyelocytic leukemia
51. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
52. 3) in the treatment of acute promyelocytic leukemia (APL): II Clinical efficacy and pharmacokinetics in relapsed patients
53. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
54. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
55. Advances in the treatment of relapsed acute promyelocytic leukemia
56. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
57. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
58. Arsenic trioxide (ATO): Analysis of QT prolongation on electrocardiogram (ECG)
59. Arsenic trioxide in relapsed or acute promyelocytic leukemia - An NCI special exception (compassionate use) program
60. Safety experience with trisenox (Arsenic trioxide) injection
61. 3 exerts dose-dependent dual effects on APL cells
62. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells
63. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
64. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins
65. PML induces a novel caspase-independent death process
66. The function of PML in p53-dependent apoptosis
67. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
68. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis
69. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
70. Molecular targets of arsenic trioxide in malignant cells
71. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis
72. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
73. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
74. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
75. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
76. Arsenic trioxide and ascorbic acid induced apoptosis in primary myeloma cells from chemoresistant patients
77. Enhanced cytotoxicity to arsenic trioxide in resistant multiple myeloma by butathione sulfoxime (BSO)
78. 3-resistant APL cells
79. Ascorbic acid potentiates arsenic trioxide-mediated cell death of multiple myeloma cells
80. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
81. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms
82. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
83. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines
84. 3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages
85. L
86. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
87. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
88. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type 1 infected T-cell lines more effectively than retinoic acids
89. Arsenic-induced apoptosis in malignant cells in vitro
90. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
91. 3) on myeloma cells
92. The development of a model for the homing of multiple myeloma cells to human bone marrow
93. Arsenic trioxide: An emerging therapy for multiple myeloma
94. Nontraditional cytotoxic therapies for relapsed/ refractory multiple myeloma
95. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity
96. Use of arsenic trioxide in the treatment of chronic myelogenous leukemia: Clinical efficacy in 34 patients
97. In vitro and in vivo effectiveness of arsenic trioxide in a murine form of T prolymphocytic leukemia (T-PLL)
98. Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia?
99. 3 in patients with relapsed/refractory adult T-cell leukemia (ATL)
100. 3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl -positive acute leukemia cells
101. Multifaceted approach to the treatment of Bcr-Abl-positive leukemias
102. Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
103. New approaches to the treatment of myelodysplasia